Published in Psychopharmacology (Berl) on December 04, 2008
Antipsychotic drugs and obesity. Trends Mol Med (2010) 1.21
Acute exposure to a high-fat diet alters meal patterns and body composition. Physiol Behav (2010) 1.07
Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat. Transl Psychiatry (2013) 1.03
Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes (2010) 0.88
Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism. Physiol Behav (2011) 0.86
Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. PLoS One (2012) 0.83
Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS One (2011) 0.83
Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats. Psychopharmacology (Berl) (2009) 0.79
A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats. Cell Mol Neurobiol (2011) 0.78
Effect of atypical antipsychotics on fetal growth: is the placenta involved? J Pregnancy (2012) 0.77
Atypical antipsychotics and effects on feeding: from mice to men. Psychopharmacology (Berl) (2016) 0.76
Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatment. PLoS One (2012) 0.75
Using Animal Models to Determine the Role of Gustatory Neural Input in the Control of Ingestive Behavior and the Maintenance of Body Weight. Chemosens Percept (2015) 0.75
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry (1999) 8.04
A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature (1996) 3.79
SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology (1997) 1.76
Neuropeptide Y: a potent inducer of consummatory behavior in rats. Peptides (1985) 1.75
Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology (2006) 1.60
Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res (2004) 1.58
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry (2001) 1.35
The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin. J Endocrinol (1999) 1.28
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry (2002) 1.21
Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci (2002) 1.20
Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist and d-fenfluramine on feeding patterns in the rat. Psychopharmacology (Berl) (2000) 1.13
Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) (2006) 1.09
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol (2007) 1.07
Melanin-concentrating hormone: a functional melanocortin antagonist in the hypothalamus. Am J Physiol (1998) 1.07
A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) (2005) 1.04
Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol Psychiatry (2007) 1.01
Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav (2003) 1.00
Different behavioral effects of haloperidol, clozapine and thioridazine in a concurrent lever pressing and feeding procedure. Psychopharmacology (Berl) (1996) 0.97
An animal model of antipsychotic-induced weight gain. Behav Brain Res (2004) 0.97
Energy expenditure and physical activity in clozapine use: implications for weight management. Aust N Z J Psychiatry (2006) 0.97
Effects of dopamine D1 and dopamine D2 antagonists on the free feeding and drinking patterns of rats. Behav Neurosci (1991) 0.95
The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology (Berl) (2007) 0.95
Antipsychotic medication, sedation and mental clouding: an observational study of psychiatric consultations. Soc Sci Med (2007) 0.95
Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res (1999) 0.94
Effects of antipsychotic drugs on operant responding after acute and repeated administration. Psychopharmacology (Berl) (2002) 0.93
Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol (2006) 0.93
Meal patterning in rodents: psychopharmacological and neuroanatomical studies. Neurosci Biobehav Rev (2000) 0.93
Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology (Berl) (2003) 0.91
Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol (2002) 0.89
Meal patterns of free feeding rats treated with clozapine, olanzapine, or haloperidol. Pharmacol Biochem Behav (2002) 0.87
Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats. Neuropeptides (2006) 0.86
Mechanism of the neuroleptic-induced obesity in female rats. Prog Neuropsychopharmacol Biol Psychiatry (1998) 0.85
The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. J Psychopharmacol (2002) 0.84
Weight changes during clozapine treatment. Aust N Z J Psychiatry (1998) 0.84
Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci (2007) 0.84
The atypical antipsychotics risperidone, clozapine and olanzapine differ regarding their sedative potency in rats. Neuropsychobiology (2003) 0.83
A model for antipsychotic-induced obesity in the male rat. Psychopharmacology (Berl) (2006) 0.83
Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study. Pharmacopsychiatry (2002) 0.82
Comparative effects of olanzapine and ziprasidone on hypophagia induced by enhanced histamine neurotransmission in the rat. Behav Pharmacol (2008) 0.81
Influence of chronic treatment with olanzapine, clozapine and scopolamine on performance of a learned 8-arm radial maze task in rats. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.81
Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol (2004) 0.81
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacology (2008) 0.80
Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus. J Psychopharmacol (2006) 0.80
Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology (Berl) (2005) 0.80
Clozapine's effects on body weight and resting metabolic rate: a case series. Schizophr Res (2004) 0.79
Partial reversal of fluoxetine anorexia by the 5-HT antagonist metergoline. Psychopharmacology (Berl) (1992) 0.78
The role of dopamine in the control of neuropeptide Y neurons in the rat arcuate nucleus. Neurosci Lett (1986) 0.78
Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats. Psychopharmacology (Berl) (2005) 0.77
Long-term treatment with chlorpromazine and haloperidol but not with sulpiride and clozapine markedly elevates neuropeptide Y-like immunoreactivity in the rat hypothalamus. Neuropeptides (1996) 0.77
Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats. Neuropsychopharmacology (2005) 0.76
Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. Int Clin Psychopharmacol (2003) 0.75
Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine. Behav Pharmacol (2006) 0.75
Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron (2006) 2.16
Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab (2007) 1.70
Long-lasting changes in behavioural and neuroendocrine indices in the rat following neonatal maternal separation: gender-dependent effects. Brain Res (2006) 1.12
The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food. Psychopharmacology (Berl) (2004) 1.07
5-HT(2C) receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice. Eur J Neurosci (2007) 1.03
The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav (2006) 0.97
Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression. J Neurogenet (2011) 0.97
Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav (2002) 0.92
Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology (Berl) (2003) 0.91
5-HT1B receptors modulate components of satiety in the rat: behavioural and pharmacological analyses of the selective serotonin1B agonist CP-94,253. Psychopharmacology (Berl) (2002) 0.90
A comparison of the effects of the CB(1) receptor antagonist SR141716A, pre-feeding and changed palatability on the microstructure of ingestive behaviour. Psychopharmacology (Berl) (2007) 0.88
Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics. Psychopharmacology (Berl) (2010) 0.87
Meal patterns of free feeding rats treated with clozapine, olanzapine, or haloperidol. Pharmacol Biochem Behav (2002) 0.87
Individual differences in locomotor reactivity to a novel environment and sensitivity to opioid drugs in the rat. II. Agonist-induced antinociception and antagonist-induced suppression of fluid consumption. Psychopharmacology (Berl) (2004) 0.86
Locomotor response to novelty as a predictor of reactivity to aversive stimuli in the rat. Brain Res (2007) 0.86
MPOA cytotoxic lesions and maternal behavior in the rat: effects of midpubertal lesions on maternal behavior and the role of ovarian hormones in maturation of MPOA control of maternal behavior. Horm Behav (2002) 0.85
Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in mice. Psychopharmacology (Berl) (2013) 0.84
Reduced hypophagic effects of d-fenfluramine and the 5-HT2C receptor agonist mCPP in 5-HT1B receptor knockout mice. Psychopharmacology (Berl) (2004) 0.84
The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. Epilepsy Res (2009) 0.83
Comparative effects of olanzapine and ziprasidone on hypophagia induced by enhanced histamine neurotransmission in the rat. Behav Pharmacol (2008) 0.81
Serotonergic and histaminergic mechanisms involved in intralipid drinking? Pharmacol Biochem Behav (2003) 0.81
Acetylcholine binding protein of mollusks is unlikely to act as a regulator of cholinergic neurotransmission at neurite-neurite synaptic sites in vivo. FASEB J (2009) 0.80
The anorectic effect of the selective dopamine D1-receptor agonist A-77636 determined by meal pattern analysis in free-feeding rats. Eur J Pharmacol (2006) 0.79
Tonic regulation of satiety by 5-HT receptors in the mouse: converging evidence from behavioural and c-fos immunoreactivity studies? Eur J Neurosci (2004) 0.78
Characterization of NO-sensitive guanylyl cyclase: expression in an identified interneuron involved in NO-cGMP-dependent memory formation. Eur J Neurosci (2008) 0.78
Dissociable effects of 5-HT2C receptor antagonism and genetic inactivation on perseverance and learned non-reward in an egocentric spatial reversal task. PLoS One (2013) 0.78
WO03/062224 is an in vivo selective agonist at nicotinic beta4 receptors. Pharmacol Biochem Behav (2008) 0.77
Animal models to explore the effects of CNS drugs on food intake and energy expenditure. Neuropharmacology (2012) 0.76
Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats. Neuropsychopharmacology (2005) 0.76
Intra-accumbens baclofen, but not muscimol, increases second order instrumental responding for food reward in rats. PLoS One (2012) 0.75